Basic characteristics and treatment regimens in people with type 2 diabetes in the international diabetes management practices study (IDMPS)

HANCU N; BAIK SH; FERREIRA S; GAGLIARDINO JJ; CHAN J; ASCHNER P; RAMACHANDRAN A; TWIGG S; ILKOVA H

Dinamarca

Congreso; 42nd Annual Meeting of the European Association for the Study of Diabetes; 2006

European Association for the Study of Diabetes

Background and Aims: The IDMPS is a multinational observational study that aims to gather data that reflect current care practices of people with diabetes in different areas of the world and to evaluate the compliance with international care guidelines. Materials and Methods: Data are being collected from type 2 diabetic patients (Q18 years) in 1-year cycles (a 2-week cross-sectional period followed by a 9-month longitudinal period) for 5 years. Data from the first crosssectional period are currently available from 7543 people (48% men) in 11 countries in Eastern Europe, Asia, and Latin America. Results: The mean age was 58T11 years, meanBMI 27T5 kg/m2 (men: 26T4 kg/m2 , women: 27T5 kg/m2 ) and mean disease duration 8 years. Mean HbA1c was 7.7T1.75% and 38% of people had an HbA1c <7%. Among people with HbA1c <7%, 4% were treated with diet and exercise only, 77% with oral  ntihyperglyemic agents (OHAs) alone and 19% with insulinTOHAs. A regimen of diet and exercise was reported in 3% of people (mean HbA1c of 6.9T1.67%). OHAs alone were used by 67% of people (mean HbA1c of 7.4T1.60%). InsulinTOHAs were used by 16% of people (average insulin dose 36 IU, mean HbA1c of 8.3T1.89%). Mean FBG (laboratory) was 152T60 mg/dL. Mean systolic/diastolic blood pressure was 135/81 mmHg. Target treatment values were obtained for LDL (<100 mg/dL) in 34% of people, HDL (>40 mg/dL) in 64% of people, and triglycerides (<150 mg/dL) in 48% of people. Conclusion: As can be seen, despite the evidence provided by the UKPDS and the recommendations of the ADA, the majority of people did not achieve the recommended treatment goals for HbA1c and FBG. It is thus apparent that more efficient guidance and education be made available to improve treatment outcomes in people with type 2 diabetes world wide.